Becton Dickinson (BDX) is receiving mixed reviews in the market, with claims that the stock may be underperforming the healthcare sector. However, some financial analysts strongly believe in the stock's long-term growth capabilities. It's mentioned multiple times that BDX is a strong growth stock, value stock, and momentum stock. Some concern exists regarding insider sell, with reports indicating that Richard Byrd sold some of his shares in the company. On a brighter note, Becton Dickinson's board has approved the repurchase of 10 million additional shares and increased the dividend for the 53rd consecutive year. The company's revenue growth stays strong, surpassing developer estimates in Q1 of 2025. Interesting developments include the completed acquisition of the critical care unit from Edwards Lifesciences, and plans to enhance focus and unlock value by separating the diagnostic solutions and Biosciences business, the latter touted to reach $30 billion in valuation. Furthermore, the U.S. manufacturing of critical medical devices is set to be ramped up and the intent to sell the life sciences division has been declared, though the shareholders have approved all board nominees.
Becton Dickinson and BDX News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Sat, 22 Mar 2025 19:16:49 GMT -
Rating 4
- Innovation 6
- Information 7
- Rumor -2
